Table 2.

Patient demographics, disease parameters, and baseline biomarker serum concentrations from MOBILITY part B biomarker analysis

	Placebo + MTX (n = 128)	Sarilumab 200 mg q2w + MTX (n = 131)	Totala (n = 259)
Baseline demographic and disease parameters
Age, mean ± SD, years	51.1 ± 10.6	49.3 ± 12.3	50.2 ± 11.5
Sex, female, %	77.3	84.7	81.1
Duration of RA, mean ± SD, years	9.1 ± 8.2	8.1 ± 6.7	8.6 ± 7.5
Anti-CCP antibody positive, %	82.8	87.0	84.9
Rheumatoid factor positive, %	87.5	87.8	87.6
Tender joint count, mean ± SD	27.3 ± 14.8	25.9 ± 14.5	26.6 ± 14.7
Swollen joint count, mean ± SD	15.8 ± 8.0	16.6 ± 10.6	16.2 ± 9.4
CRP, mean ± SD, mg/dL	1.7 ± 1.9	2.1 ± 2.1	1.9 ± 2.0
mTSS, mean ± SD	51.8 ± 72.1	45.9 ± 60.2	48.8 ± 66.3
Baseline biomarker serum concentrations, median (quartile 1/quartile 3)
C1M, ng/mL	114.0 (77.0/175.7)	120.5 (86.1/196.3)	119.6 (80.7/184.2)
C2M, ng/mL	0.3 (0.2/0.4)	0.3 (0.2/0.4)	0.3 (0.2/0.4)
C3M, ng/mL	43.1 (34.6/58.0)	45.4 (34.4/60.5)	44.2 (34.5/59.9)
CTX-1, ng/mL	0.4 (0.3/0.6)	0.4 (0.3/0.5)	0.4 (0.3/0.5)
MMP-3, ng/mL	41.9 (24.6/77.6)	38.9 (21.3/68.7)	40.3 (22.3/73.1)
OC, ng/mL	18.3 (13.0/25.0)	18.6 (14.6/24.7)	18.5 (13.5/24.7)
OPG, pmol/L	4.9 (3.9/6.3)	5.4 (3.9/6.7)	5.2 (3.9/6.5)
sRANKL, pmol/L	1012.5 (385.0/3893.0)	1096.0 (393.0/2161.5)	1026.0 (387.0/2748.5)
sRANKL/OPG	245.1 (64.4/836.5)	186.3 (71.8/401.2)	212.6 (70.8/509.7)

^aAll patients receiving placebo or sarilumab 200 mg q2w. C1M collagen type I MMP-cleaved fragment, C2M collagen type II MMP-cleaved fragment, C3M collagen type III MMP-cleaved fragment, CCP cyclic citrullinated peptide, CRP C-reactive protein, CTX-1 carboxy-terminal collagen crosslinks 1, MMP matrix metalloproteinase, mTSS van der Heijde modified total Sharp score, MTX methotrexate, OC osteocalcin, OPG osteoprotegerin, q2w every 2 weeks, RA rheumatoid arthritis, SD standard deviation, sRANKL soluble receptor activator of nuclear factor-kB ligand